Betulinic acid
Based on 35 publication(s) in Google Scholar
Betulinic acid is a natural pentacyclic triterpenoid, acts as a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and possesses anti-HIV, anti-malarial, anti-inflammatory and anti-tumor properties. Betulinic acid can cross the blood-brain barrier.
For research use only. We do not sell to patients.
- Purity: 99.88%
- CAS No.: 472-15-1
- Formula: C30H48O3
- Molecular Weight:456.70
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Betulinic acid
More- Sci Bull. 2023 Dec 30;68(24):3207-3224. [Abstract]
- Theranostics. 2022 May 1;12(8):3656-3675. [Abstract]
- Pharmacol Res. 2024 May 9:204:107208. [Abstract]
- Int J Biol Sci. 2021 Mar 11;17(4):1138-1152. [Abstract]
- Green Chem. 2019, 21, 3370-3382.
- Phytomedicine. 2025 Dec 24:150:157740. [Abstract]
- J Transl Med. 2025 Nov 13;23(1):1282. [Abstract]
- Fuel. 2018 Dec 15, 234:110-119.
- Biochem Pharmacol. 2026 May:247:117771. [Abstract]
- Catal Today. 2020 Aug.
- Nutrients. 2025 Jun 20;17(13):2052. [Abstract]
- Microb Cell Fact. 2019 May 3;18(1):77. [Abstract]
- Front Pharmacol. 2019 Sep 13;10:1017. [Abstract]
- Int Immunopharmacol. 2025 Aug 11:164:115325. [Abstract]
- mBio. 2025 Jan 31:e0302024. [Abstract]
- Front Cell Dev Biol. 2021 Apr 6:9:658757. [Abstract]
- J Cell Mol Med. 2026 Jan;30(1):e71000. [Abstract]
- Drug Dev Res. 2025 Aug;86(5):e70140. [Abstract]
- J Food Biochem. 2025 Jun 13.
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Aging (Albany NY). 2021 Sep 12;13(17):21251-21267. [Abstract]
- Heliyon. 2023 Dec 29;10(1):e23833. [Abstract]
- Heliyon. 2023 Nov 20;9(12):e22599. [Abstract]
- Heliyon. 2023 Jun 22;9(6):e17595. [Abstract]
- Mol Med Rep. 2024 Nov;30(5):209. [Abstract]
- Mol Med Rep. 2022 Apr;25(4):134. [Abstract]
- Wound Repair Regen. 2022 May;30(3):376-396. [Abstract]
- Gut Liver. 2024 May 15;18(3):414-425. [Abstract]
- Cell Immunol. 2022 Feb:372:104475. [Abstract]
- J Cell Biochem. 2023 Nov;124(11):1667-1684. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Virus Res. 2023 Aug:333:199139. [Abstract]
- J Gene Med. 2025 Feb;27(2):e70011. [Abstract]
- Med Sci Monit. 2020 Dec 3:26:e926281. [Abstract]
- Nat Prod Commun. July 21, 2022.
-
Bio/Physico-chemical Assay
-
In Vivo Efficacy Study
-
WB
-
Histological Imaging/Staining
-
IF
All Topoisomerase Isoforms
MoreAll Endogenous Metabolite Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
Topoisomerase I 5 μM (IC50) |
HIV-1 1.4 μM (EC50) |
NF-κB |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
14.04 μM
Compound: BA
|
Cytotoxicity against mouse 4T1 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against mouse 4T1 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| 518A2 | IC50 |
11.9 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| 518A2 | IC50 |
11.9 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| 518A2 | IC50 |
8.13 μM
Compound: 1
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| 518A2 | IC50 |
8.13 μM
Compound: 1
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| 518A2 | IC50 |
11.9 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| 518A2 | IC50 |
11.9 μM
Compound: 2, BA
|
Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| 518A2 | IC50 |
14.8 μM
Compound: 1
|
Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| 518A2 | IC50 |
11.9 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 24161703] |
| 518A2 | EC50 |
11.9 μM
Compound: Betulinic acid
|
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| 518A2 | EC50 |
9.4 μM
Compound: 1
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| 518A2 | EC50 |
9.4 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| 518A2 | EC50 |
9.4 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 27017553] |
| 518A2 | EC50 |
11.9 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 27142753] |
| 518A2 | EC50 |
9.4 μM
Compound: 4; BA
|
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| 518A2 | EC50 |
9.4 μM
Compound: 5
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| 518A2 | EC50 |
13.6 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| 518A2 | EC50 |
9.4 μM
Compound: BA
|
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 30278332] |
| 518A2 | EC50 |
11.9 μM
Compound: BA
|
Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| 518A2 | IC50 |
0.33 μM
Compound: 1
|
Antitumor activity against human 518A2 cells by SRB assay
Antitumor activity against human 518A2 cells by SRB assay
|
[PMID: 31499360] |
| 8505C | IC50 |
6.7 μM
Compound: BA
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| 8505C | IC50 |
6.7 μM
Compound: BA
|
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| 8505C | IC50 |
7.26 μM
Compound: 1
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| 8505C | IC50 |
6.7 μM
Compound: BA
|
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| 8505C | IC50 |
6.7 μM
Compound: 2, BA
|
Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| 8505C | IC50 |
12.63 μM
Compound: 1
|
Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| 8505C | IC50 |
6.7 μM
Compound: BA
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 24161703] |
| 8505C | EC50 |
6.7 μM
Compound: Betulinic acid
|
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| 8505C | EC50 |
6.7 μM
Compound: BA
|
Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| 8505C | IC50 |
0.33 μM
Compound: 1
|
Antitumor activity against human 8505C cells by SRB assay
Antitumor activity against human 8505C cells by SRB assay
|
[PMID: 31499360] |
| A253 cell line | IC50 |
11.1 μM
Compound: BA
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| A253 cell line | IC50 |
11.1 μM
Compound: BA
|
Cytotoxicity against human A253 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A253 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| A253 cell line | IC50 |
9.18 μM
Compound: 1
|
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
Cytotoxicity against human A253 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| A253 cell line | IC50 |
9.18 μM
Compound: 1
|
Cytotoxicity against human A253 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A253 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A253 cell line | IC50 |
11.1 μM
Compound: BA
|
Cytotoxicity against human A253 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A253 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| A253 cell line | IC50 |
11.1 μM
Compound: 2, BA
|
Cytotoxicity against human A253 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A253 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| A2780 | IC50 |
>=20 μg/mL
Compound: 7
|
Cytotoxicity against human A2780 cells
Cytotoxicity against human A2780 cells
|
[PMID: 12662105] |
| A2780 | IC50 |
11 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| A2780 | IC50 |
11 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| A2780 | IC50 |
11.07 μM
Compound: 1
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| A2780 | IC50 |
11.07 μM
Compound: 1
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A2780 | IC50 |
11 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| A2780 | IC50 |
11 μM
Compound: 2, BA
|
Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| A2780 | IC50 |
8.75 μM
Compound: 1
|
Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| A2780 | IC50 |
11 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 24161703] |
| A2780 | EC50 |
11 μM
Compound: Betulinic acid
|
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| A2780 | EC50 |
8.8 μM
Compound: 1
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| A2780 | EC50 |
8.8 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| A2780 | EC50 |
8.8 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 27017553] |
| A2780 | EC50 |
11 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 27142753] |
| A2780 | EC50 |
8.8 μM
Compound: 4; BA
|
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| A2780 | EC50 |
8.8 μM
Compound: 5
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| A2780 | EC50 |
12.7 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| A2780 | EC50 |
12.7 μM
Compound: BA
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910] |
| A2780 | EC50 |
11 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 29960206] |
| A2780 | EC50 |
9.7 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay
|
[PMID: 30056282] |
| A2780 | EC50 |
8.8 μM
Compound: BA
|
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 30278332] |
| A2780 | EC50 |
12.7 μM
Compound: BA
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925] |
| A2780 | EC50 |
12.7 μM
Compound: BA
|
Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| A2780 | IC50 |
0.33 μM
Compound: 1
|
Antitumor activity against human A2780 cells by SRB assay
Antitumor activity against human A2780 cells by SRB assay
|
[PMID: 31499360] |
| A2780 | EC50 |
8.8 μM
Compound: BA
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| A2780 | EC50 |
>30 μM
Compound: 1
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| A-375 | IC50 |
51 μM
Compound: 7
|
Antiproliferative activity against human A375 cells after 72 hrs by MTS assay
Antiproliferative activity against human A375 cells after 72 hrs by MTS assay
|
[PMID: 19286375] |
| A-375 | IC50 |
22 μM
Compound: 1
|
Cytotoxicity against human A375 cells after 72 hrs by MTS assay
Cytotoxicity against human A375 cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| A-375 | IC50 |
43.7 μM
Compound: BA
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28368586] |
| A-375 | EC50 |
12 μM
Compound: BA
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910] |
| A-375 | EC50 |
17.1 μM
Compound: BA
|
Cytotoxicity against human A375 cells after 96 hrs by SRB assay
Cytotoxicity against human A375 cells after 96 hrs by SRB assay
|
[PMID: 29960206] |
| A-375 | EC50 |
>30 μM
Compound: 1
|
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| A-431 | IC50 |
15.4 μM
Compound: BA
|
Cytotoxicity against human A431 cells after 96 hrs by SRB assay
Cytotoxicity against human A431 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| A-431 | IC50 |
15.4 μM
Compound: BA
|
Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| A-431 | IC50 |
12.6 μM
Compound: 1
|
Cytotoxicity against human A431 cells after 96 hrs by SRB assay
Cytotoxicity against human A431 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| A-431 | IC50 |
12.6 μM
Compound: 1
|
Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A431 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A-431 | IC50 |
15.4 μM
Compound: BA
|
Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A431 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| A549 | ED50 |
7.7 μg/mL
Compound: BA (Betulinic acid)
|
Cytotoxic activity towards A-549 cells
Cytotoxic activity towards A-549 cells
|
[PMID: 12951080] |
| A549 | ED50 |
>10 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human A549 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| A549 | IC50 |
146 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| A549 | IC50 |
72.8 μM
Compound: 12
|
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
Antiinflammatory activity against human A549 cells assessed as inhibition of IL-1-alpha-induced ICAM1 expression treated after 1 hr before IL1alpha challenge
|
[PMID: 15730243] |
| A549 | IC50 |
85.3 μM
Compound: 12
|
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 24 hrs by MTT assay
|
[PMID: 15730243] |
| A549 | IC50 |
97.51 μM
Compound: BA
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 17275295] |
| A549 | IC50 |
6.65 μM
Compound: 3
|
Cytotoxicity against human A549 cells after 1 hr by MTT assay
Cytotoxicity against human A549 cells after 1 hr by MTT assay
|
[PMID: 18343122] |
| A549 | IC50 |
2.8 μg/mL
Compound: 9
|
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
|
[PMID: 18590313] |
| A549 | IC50 |
3 μg/mL
Compound: 1
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| A549 | IC50 |
10.3 μM
Compound: 2
|
Cytotoxicity against human A549 cells after 48 hrs
Cytotoxicity against human A549 cells after 48 hrs
|
[PMID: 19115839] |
| A549 | IC50 |
>200 μM
Compound: 1
|
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
|
[PMID: 19200744] |
| A549 | IC50 |
10.3 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
|
[PMID: 19200744] |
| A549 | IC50 |
10.3 μM
Compound: 3
|
Cytotoxicity against human A549 cells by resazurin reduction test
Cytotoxicity against human A549 cells by resazurin reduction test
|
[PMID: 19285391] |
| A549 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| A549 | IC50 |
10.82 μM
Compound: 7
|
Cytotoxicity against human A549 cells by SRB assay
Cytotoxicity against human A549 cells by SRB assay
|
[PMID: 20176479] |
| A549 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| A549 | IC50 |
11.1 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| A549 | IC50 |
11.1 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human A549 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| A549 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| A549 | IC50 |
14.9 μM
Compound: 2, BA
|
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| A549 | IC50 |
31 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| A549 | IC50 |
13.3 μM
Compound: 1
|
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| A549 | IC50 |
43.97 μM
Compound: Betulinic acid
|
Cytotoxicity against human A549 cells after 72 hrs ny MTT assay
Cytotoxicity against human A549 cells after 72 hrs ny MTT assay
|
[PMID: 23974020] |
| A549 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 24161703] |
| A549 | IC50 |
>20 μM
Compound: BetA
|
Cytotoxicity against human A549 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| A549 | EC50 |
14.8 μM
Compound: Betulinic acid
|
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| A549 | EC50 |
17.1 μM
Compound: 1
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| A549 | IC50 |
8 μM
Compound: 1
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26629862] |
| A549 | EC50 |
17.1 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| A549 | EC50 |
17.1 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 27017553] |
| A549 | EC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 27142753] |
| A549 | EC50 |
17.1 μM
Compound: 4; BA
|
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| A549 | EC50 |
17.1 μM
Compound: 5
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| A549 | EC50 |
7.6 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| A549 | IC50 |
3.1 μM
Compound: 17
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 28358502] |
| A549 | IC50 |
43.7 μM
Compound: BA
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28368586] |
| A549 | IC50 |
>10 μM
Compound: 1
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| A549 | IC50 |
17.13 μM
Compound: 2
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28671831] |
| A549 | EC50 |
17.1 μM
Compound: BA
|
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 30278332] |
| A549 | IC50 |
29.5 μM
Compound: 1; BA
|
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human A549 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| A549 | EC50 |
14.9 μM
Compound: BA
|
Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| A549 | IC50 |
0.33 μM
Compound: 1
|
Antitumor activity against human A549 cells by SRB assay
Antitumor activity against human A549 cells by SRB assay
|
[PMID: 31499360] |
| A549 | IC50 |
69.81 μM
Compound: 1; BA
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| B16 | ED50 |
4.1 μM
Compound: 11
|
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
Induction of melanogenesis in mouse B16 2F2 cells assessed as intracellular melanin content after 3 days
|
[PMID: 12027734] |
| B16 | IC50 |
7.9 μM
Compound: 11
|
Growth inhibition of mouse B16 2F2 cells after 3 days
Growth inhibition of mouse B16 2F2 cells after 3 days
|
[PMID: 12027734] |
| B16 | IC50 |
53.46 μM
Compound: BA
|
Cytotoxicity against mouse B16 cells by MTT assay
Cytotoxicity against mouse B16 cells by MTT assay
|
[PMID: 17275295] |
| B16 | IC50 |
5 μg/mL
Compound: 9
|
Cytotoxicity against mouse B16 cells
Cytotoxicity against mouse B16 cells
|
[PMID: 18590313] |
| B16-F10 | ED50 |
4.98 μg/mL
Compound: BA (Betulinic acid)
|
Cytotoxic activity towards B16-F10 cells
Cytotoxic activity towards B16-F10 cells
|
[PMID: 12951080] |
| B16-F10 | IC50 |
>20 μM
Compound: BetA
|
Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| Bel-7402 | IC50 |
43.39 μM
Compound: BA
|
Cytotoxicity against human BEL-7402 cells by MTT assay
Cytotoxicity against human BEL-7402 cells by MTT assay
|
[PMID: 17275295] |
| BMDC | IC50 |
19.45 μM
Compound: 24
|
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated TNF-alpha production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
|
[PMID: 23484668] |
| BMDC | IC50 |
21.27 μM
Compound: 24
|
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL12 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
|
[PMID: 23484668] |
| BMDC | IC50 |
3.61 μM
Compound: 24
|
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
Antiinflammatory activity in C57BL/6 mouse BMDCs assessed as inhibition of LPS-stimulated IL-12p40 production treated 1 hr before LPS challenge measured 18 hrs post stimulation by ELISA
|
[PMID: 23484668] |
| BRISTOL8 | ED50 |
0.84 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human BRISTOL8 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| BV-2 | IC50 |
4.5 μM
Compound: 17
|
Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay
|
[PMID: 28358502] |
| BXPC-3 | GI50 |
0.85 μg/mL
Compound: 2
|
Cytotoxicity against human BxPC3 cells
Cytotoxicity against human BxPC3 cells
|
[PMID: 15217278] |
| C3H 10T1/2 | IC50 |
82 μM
Compound: 2
|
Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by fluorometric microculture cytotoxicity assay
Cytotoxicity against mouse C3H10T1/2 cells after 24 hrs by fluorometric microculture cytotoxicity assay
|
[PMID: 18842418] |
| C6 | IC50 |
90.69 μM
Compound: BA
|
Cytotoxicity against mouse C6 cells by MTT assay
Cytotoxicity against mouse C6 cells by MTT assay
|
[PMID: 17275295] |
| Ca9-22 | IC50 |
>20 μg/mL
Compound: 9
|
Cytotoxicity against human sCa9-22 cells by MTT assay
Cytotoxicity against human sCa9-22 cells by MTT assay
|
[PMID: 18590313] |
| CCD-18Co | IC50 |
43.6 μM
Compound: 1
|
Cytotoxicity against human CCD-18Co cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human CCD-18Co cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| CCRF-CEM | ED50 |
0.98 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human CEM.CM3 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| CCRF-CEM | IC50 |
27 μM
Compound: 1
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| CCRF-CEM | IC50 |
30 μM
Compound: 1a
|
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CEM cells after 72 hrs by MTT assay
|
[PMID: 17371067] |
| CCRF-CEM | IC50 |
30 μM
Compound: 2
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by MTT assay
|
[PMID: 22551630] |
| CEM-SS | CC50 |
5.9 μM
Compound: 5
|
Cytotoxicity against human CEM-SS cells after 6 days by MTS assay
Cytotoxicity against human CEM-SS cells after 6 days by MTS assay
|
[PMID: 15217281] |
| CEM-SS | ED50 |
2 μM
Compound: 5
|
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
Antiviral activity against HIV1 3B infected in human CEM-SS cells assessed as inhibition of virus-induced cytopathic effect after 6 days by MTS assay
|
[PMID: 15217281] |
| CHO | EC50 |
1.04 μM
Compound: 1
|
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
Agonist activity at TGR5 expressed in CHO cells by CRE-driven luciferase reporter gene assay
|
[PMID: 19911773] |
| CHO | IC50 |
>20 μM
Compound: BetA
|
Cytotoxicity against CHO cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against CHO cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| Col2 | ED50 |
43.9 μM
Compound: 5
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 15217281] |
| Col2 | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against human Col2 cells
Cytotoxicity against human Col2 cells
|
[PMID: 16562829] |
| COS-1 | EC50 |
0 μM
Compound: 1
|
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
Agonist activity at human FXR expressed in COS1 cells by luciferase reporter gene assay
|
[PMID: 19911773] |
| Daoy | IC50 |
31 μM
Compound: 7
|
Antiproliferative activity against human DaOY cells after 72 hrs by MTS assay
Antiproliferative activity against human DaOY cells after 72 hrs by MTS assay
|
[PMID: 19286375] |
| Daoy | IC50 |
11 μM
Compound: 1
|
Cytotoxicity against human DaOY cells after 72 hrs by MTS assay
Cytotoxicity against human DaOY cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| DLD-1 | IC50 |
15 μM
Compound: 2
|
Cytotoxicity against human DLD1 cells after 48 hrs
Cytotoxicity against human DLD1 cells after 48 hrs
|
[PMID: 19115839] |
| DLD-1 | IC50 |
>200 μM
Compound: 1
|
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
|
[PMID: 19200744] |
| DLD-1 | IC50 |
15 μM
Compound: 1
|
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
|
[PMID: 19200744] |
| DLD-1 | IC50 |
15 μM
Compound: 3
|
Cytotoxicity against human DLD1 cells by resazurin reduction test
Cytotoxicity against human DLD1 cells by resazurin reduction test
|
[PMID: 19285391] |
| DLD-1 | IC50 |
17.5 μM
Compound: BA
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| DLD-1 | IC50 |
17.5 μM
Compound: BA
|
Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| DLD-1 | IC50 |
11.87 μM
Compound: 1
|
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| DLD-1 | IC50 |
17.5 μM
Compound: BA
|
Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human DLD1 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| DLD-1 | IC50 |
17.5 μM
Compound: 2, BA
|
Cytotoxicity against human DLD1 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human DLD1 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| DU-145 | GI50 |
5 μg/mL
Compound: 2
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 15217278] |
| DU-145 | ED50 |
1.13 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human DU145 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| DU-145 | IC50 |
196 μM
Compound: 1
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| DU-145 | GI50 |
35.3 μg/mL
Compound: 1
|
Cytotoxicity against human DU145 cells
Cytotoxicity against human DU145 cells
|
[PMID: 18163590] |
| DU-145 | IC50 |
>20 μg/mL
Compound: 1
|
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| DU-145 | IC50 |
37 μM
Compound: 2
|
Cytotoxicity against human DU145 cells after 24 hrs by fluorometric microculture cytotoxicity assay
Cytotoxicity against human DU145 cells after 24 hrs by fluorometric microculture cytotoxicity assay
|
[PMID: 18842418] |
| DU-145 | IC50 |
22 μM
Compound: 1
|
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
Cytotoxicity against human DU145 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| DU-145 | IC50 |
36.16 μM
Compound: BA
|
Cytotoxicity against human DU145 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human DU145 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| DU-145 | CC50 |
>500 μM
Compound: 5
|
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
Cytotoxic activity in human DU145 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| DU-145 | IC50 |
>500 μM
Compound: 5
|
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
Antiproliferative activity in human DU145 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| ECa-109 cell line | IC50 |
28.07 μM
Compound: 2
|
Cytotoxicity against human ECA109 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human ECA109 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28671831] |
| ECV-304 | IC50 |
1.26 μg/mL
Compound: 1, Betulinic acid
|
Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304
Half-maximal cytotoxic concentration of compound against endothelial cell line ECV304
|
[PMID: 15081004] |
| ECV-304 | IC50 |
1.2 μg/mL
Compound: 1
|
Cytotoxic activity against ECV304 (human endothelial) cell line.
Cytotoxic activity against ECV304 (human endothelial) cell line.
|
[PMID: 15149668] |
| Ehrlich | IC50 |
54 μM
Compound: 1
|
Cytotoxicity against mouse Ehrlich carcinoma cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse Ehrlich carcinoma cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31499360] |
| Epithelial cell | IC50 |
>20 μM
Compound: betulinic acid
|
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
Antiproliferative activity against mouse +SA mammary epithelial cells after 4 days by MTT assay
|
[PMID: 18826277] |
| FaDu | IC50 |
10.4 μM
Compound: BA
|
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| FaDu | IC50 |
10.4 μM
Compound: BA
|
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| FaDu | IC50 |
10.19 μM
Compound: 1
|
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| FaDu | IC50 |
10.4 μM
Compound: BA
|
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| FaDu | EC50 |
15.3 μM
Compound: BA
|
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| FaDu | EC50 |
15.3 μM
Compound: 4; BA
|
Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human FADU cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| FaDu | EC50 |
13.7 μM
Compound: BA
|
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
Cytotoxicity against human FADU cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| FaDu | EC50 |
13.4 μM
Compound: BA
|
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910] |
| FaDu | EC50 |
10.7 μM
Compound: BA
|
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay
|
[PMID: 30056282] |
| FaDu | EC50 |
13.4 μM
Compound: BA
|
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925] |
| FaDu | EC50 |
>30 μM
Compound: 1
|
Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human FaDu cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| Fibroblast | IC50 |
20.81 μM
Compound: 1
|
Cytotoxicity against human fibroblast after 96 hrs by SRB assay
Cytotoxicity against human fibroblast after 96 hrs by SRB assay
|
[PMID: 20451375] |
| H9 | EC50 |
1.4 μM
Compound: 1
|
Cytotoxicity against mock-infected human H9 cells
Cytotoxicity against mock-infected human H9 cells
|
[PMID: 11141100] |
| H9 | IC50 |
12.9 μM
Compound: 1
|
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
Antiviral activity against HIV1 3B isolate replication in human H9 cells assessed as decrease in viral p24 level after 4 days
|
[PMID: 11141100] |
| H9 | IC50 |
12.9 μM
Compound: 1, Betulinic acid
|
Concentration required to produce 50% toxicity against mock-infected H9 cells
Concentration required to produce 50% toxicity against mock-infected H9 cells
|
[PMID: 15501054] |
| H9 | EC50 |
1.4 μM
Compound: 130
|
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
Antiviral activity against HIV1 3B infected in H9 cells assessed as inhibition of viral replication by p24 antigen ELISA
|
[PMID: 20187635] |
| H9 | EC50 |
1.4 μM
Compound: 130
|
Antiviral activity against HIV1 infected in human H9 cells after 4 days by p24 antigen ELISA
Antiviral activity against HIV1 infected in human H9 cells after 4 days by p24 antigen ELISA
|
[PMID: 20187635] |
| H9 | IC50 |
13 μM
Compound: 130
|
Cytotoxicity against human H9 cells after 4 days by coulter counter
Cytotoxicity against human H9 cells after 4 days by coulter counter
|
[PMID: 20187635] |
| H9 | EC50 |
1.4 μM
Compound: 1
|
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of viral replication after 3 days by p24 antigen capture assay
|
[PMID: 8176401] |
| H9 | IC50 |
13 μM
Compound: 1
|
Cytotoxicity against human H9 cells after 3 days
Cytotoxicity against human H9 cells after 3 days
|
[PMID: 8176401] |
| H9 | EC50 |
1.4 μM
Compound: 1
|
Toxic concentration on HIV-1 mock infected H9 lymphocyte cells
Toxic concentration on HIV-1 mock infected H9 lymphocyte cells
|
[PMID: 8676334] |
| H9 | IC50 |
13 μM
Compound: 1
|
Inhibitory activity against HIV-1 replication in mock infected H9 cells
Inhibitory activity against HIV-1 replication in mock infected H9 cells
|
[PMID: 8676334] |
| H9 | EC50 |
1.4 μM
Compound: 1
|
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound able to suppress HIV replication by 50%.
|
[PMID: 9804704] |
| H9 | IC50 |
13 μM
Compound: 1
|
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.
Anti-HIV activity against acutely infected H9 lymphocytes. Activity expressed as concentration of compound toxic to 50% of mock-infected H9 cells.
|
[PMID: 9804704] |
| H9 | EC50 |
1.4 μM
Compound: 1, Betulinic acid
|
Compound was evaluated for anti-HIV activity in H9 lymphocytes
Compound was evaluated for anti-HIV activity in H9 lymphocytes
|
[PMID: 9871747] |
| H9 | IC50 |
13 μM
Compound: 1, Betulinic acid
|
Compound was evaluated for cytotoxicity in H9 lymphocytes
Compound was evaluated for cytotoxicity in H9 lymphocytes
|
[PMID: 9871747] |
| H9 | EC50 |
1.4 μM
Compound: 1, BA
|
Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication
Antiviral activity against Human immunodeficiency virus 1 infected human H9 cells assessed as inhibition of viral replication
|
10.1007/s00044-010-9467-2 |
| HaCaT | IC50 |
32 μM
Compound: 2
|
Inhibition of GLI1-mediated transcriptional activity in human HaCaT cells by luciferase based reporter gene assay
Inhibition of GLI1-mediated transcriptional activity in human HaCaT cells by luciferase based reporter gene assay
|
[PMID: 18842418] |
| HBL-100 | IC50 |
5.02 μg/mL
Compound: 1
|
Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| HCT-116 | GI50 |
2.7 μM
Compound: 1
|
Cytotoxicity of compound against human colon carcinoma (HCT116) using MTT assay
Cytotoxicity of compound against human colon carcinoma (HCT116) using MTT assay
|
[PMID: 11527742] |
| HCT-116 | IC50 |
13.46 μM
Compound: 1
|
Antiproliferative activity against human HCT116 cells after 3 days by XTT assay
Antiproliferative activity against human HCT116 cells after 3 days by XTT assay
|
[PMID: 19691293] |
| HCT-116 | IC50 |
13.3 μM
Compound: BA
|
Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| HCT-116 | IC50 |
13.3 μM
Compound: BA
|
Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| HCT-116 | IC50 |
10.8 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay
Cytotoxicity against human HCT116 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| HCT-116 | IC50 |
13.3 μM
Compound: BA
|
Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HCT116 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| HCT-116 | IC50 |
22.13 μM
Compound: BA
|
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| HCT-116 | IC50 |
>10 μM
Compound: 1
|
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human HCT116 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| HCT-15 | IC50 |
14.25 μM
Compound: 7
|
Cytotoxicity against human HCT15 cells by SRB assay
Cytotoxicity against human HCT15 cells by SRB assay
|
[PMID: 20176479] |
| HCT-15 | IC50 |
12 μM
Compound: 1
|
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
Cytotoxicity against human HCT15 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| HCT-15 | IC50 |
8.7 μM
Compound: 17
|
Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human HCT15 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 28358502] |
| HCT-8 | IC50 |
17.8 μM
Compound: BA
|
Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay
Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| HCT-8 | IC50 |
17.8 μM
Compound: BA
|
Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| HCT-8 | IC50 |
13.1 μM
Compound: 1
|
Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay
Cytotoxicity against human HCT8 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| HCT-8 | IC50 |
17.8 μM
Compound: BA
|
Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HCT8 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| HEK293 | EC50 |
>100 μM
Compound: 19
|
Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay
Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay
|
[PMID: 24955889] |
| HEK293 | CC50 |
80 μM
Compound: 5
|
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
Cytotoxic activity in HEK293 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HEK293 | IC50 |
336.2 μM
Compound: 5
|
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
Antiproliferative activity in HEK293 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HeLa | IC50 |
26 nM
Compound: 2
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 19674909] |
| HeLa | IC50 |
26 μM
Compound: 2
|
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 20494586] |
| HeLa | EC50 |
8.8 μM
Compound: BA
|
Cytotoxicity against human HeLa cells after 96 hrs by SRB assay
Cytotoxicity against human HeLa cells after 96 hrs by SRB assay
|
[PMID: 27142753] |
| HeLa | CC50 |
32.6 μM
Compound: 5
|
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
Cytotoxic activity in human HeLa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HeLa | IC50 |
47.6 μM
Compound: 5
|
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
Antiproliferative activity in human HeLa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HeLa | IC50 |
10 μM
Compound: BA
|
Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 30 mins by CCK-8 method
Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 30 mins by CCK-8 method
|
[PMID: 38039788] |
| HeLa | IC50 |
10.52 μM
Compound: BA
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| HeLa | IC50 |
12.28 μM
Compound: BA
|
Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 20 mins by CCK-8 method
Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 20 mins by CCK-8 method
|
[PMID: 38039788] |
| HeLa | IC50 |
18.24 μM
Compound: BA
|
Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 10 mins by CCK-8 method
Phototoxicity against human HeLa cells assessed as reduction in cell viability pre-incubated for 3 hrs followed by 20mW/cm2 white light irradiation and measured after 10 mins by CCK-8 method
|
[PMID: 38039788] |
| HeLa | IC50 |
35.61 μM
Compound: BA
|
Phototoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 hrs under dark condition by CCK-8 method
Phototoxicity against human HeLa cells assessed as reduction in cell viability incubated for 3 hrs under dark condition by CCK-8 method
|
[PMID: 38039788] |
| HeLa | IC50 |
31.27 μM
Compound: 1; BA
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| HeLa | IC50 |
0.8 μg/mL
Compound: betulinicacidbetulinic acid
|
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 9834149] |
| Hep 3B2 | IC50 |
1.7 μg/mL
Compound: 9
|
Cytotoxicity against human Hep3B cells by MTT assay
Cytotoxicity against human Hep3B cells by MTT assay
|
[PMID: 18590313] |
| HEp-2 | IC50 |
16 μM
Compound: 1
|
Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay
Cytotoxicity against human Hep2 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| HEp-2 | CC50 |
48.2 μM
Compound: 5
|
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
Cytotoxic activity in human Hep2 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HEp-2 | IC50 |
>500 μM
Compound: 5
|
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
Antiproliferative activity in human Hep2 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| HepG2 | IC50 |
21 μM
Compound: 12
|
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Hep G2 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| HepG2 | IC50 |
3.1 μg/mL
Compound: 9
|
Cytotoxicity against human HepG2 cells by MTT assay
Cytotoxicity against human HepG2 cells by MTT assay
|
[PMID: 18590313] |
| HepG2 | IC50 |
36.4 nM
Compound: 2
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 19674909] |
| HepG2 | IC50 |
36.4 μM
Compound: 2
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 20494586] |
| HepG2 | IC50 |
23.9 μM
Compound: 1
|
Cytotoxicity against human HepG2 cells
Cytotoxicity against human HepG2 cells
|
[PMID: 25442310] |
| HepG2 | IC50 |
5.9 μM
Compound: 25
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 27617953] |
| HepG2 | IC50 |
25.3 μM
Compound: 2
|
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28671831] |
| HepG2 | CC50 |
>400 μM
Compound: BA
|
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
|
[PMID: 29326018] |
| HepG2 | IC50 |
11.74 μM
Compound: BA
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| HepG2 | IC50 |
40.03 μM
Compound: 1; BA
|
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human HepG2 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| HL-60 | IC50 |
2 μg/mL
Compound: 9
|
Cytotoxicity against human HL60 cells by MTT assay
Cytotoxicity against human HL60 cells by MTT assay
|
[PMID: 18590313] |
| HL-60 | IC50 |
17 μM
Compound: 1
|
Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
Cytotoxicity against human HL60 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| HL-60 | IC50 |
8 μM
Compound: 1
|
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26629862] |
| HL-60 | IC50 |
18.47 μM
Compound: 2
|
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28671831] |
| HPAF-II | IC50 |
12.5 μM
Compound: 1; BA
|
Antitumor activity against human HPAF-II cells measured after 72 hrs
Antitumor activity against human HPAF-II cells measured after 72 hrs
|
[PMID: 37236000] |
| HT-29 | IC50 |
89 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| HT-29 | GI50 |
30.9 μg/mL
Compound: 1
|
Cytotoxicity against human HT29 cells
Cytotoxicity against human HT29 cells
|
[PMID: 18163590] |
| HT-29 | IC50 |
37 μM
Compound: 7
|
Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay
Antiproliferative activity against human HT-29 cells after 72 hrs by MTS assay
|
[PMID: 19286375] |
| HT-29 | IC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| HT-29 | IC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| HT-29 | IC50 |
13.93 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| HT-29 | IC50 |
13.93 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| HT-29 | IC50 |
12.8 μM
Compound: 2
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 20494586] |
| HT-29 | IC50 |
31 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| HT-29 | IC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| HT-29 | IC50 |
17.32 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| HT-29 | EC50 |
13.1 μM
Compound: Betulinic acid
|
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| HT-29 | EC50 |
14.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| HT-29 | EC50 |
14.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 27017553] |
| HT-29 | EC50 |
14.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 27142753] |
| HT-29 | EC50 |
14.4 μM
Compound: 4; BA
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| HT-29 | EC50 |
14.4 μM
Compound: 5
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| HT-29 | EC50 |
18.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| HT-29 | EC50 |
18.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910] |
| HT-29 | EC50 |
14.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 29960206] |
| HT-29 | EC50 |
16 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay
|
[PMID: 30056282] |
| HT-29 | IC50 |
>10 μM
Compound: 9
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| HT-29 | IC50 |
3.5 μM
Compound: 9
|
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
Inhibition of mitochondrial membrane potential in human HT-29 cells after 3 hrs by JC-1 staining based fluorescence assay
|
[PMID: 30057155] |
| HT-29 | EC50 |
14.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 30278332] |
| HT-29 | EC50 |
18.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925] |
| HT-29 | EC50 |
18.4 μM
Compound: BA
|
Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| HT-29 | EC50 |
14.4 μM
Compound: BA
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| HT-29 | EC50 |
>30 μM
Compound: 1
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| HUVEC | ED50 |
28.7 μM
Compound: 5
|
Cytotoxicity against HUVEC cells
Cytotoxicity against HUVEC cells
|
[PMID: 15217281] |
| J774 | IC50 |
44 μM
Compound: 9
|
Cytotoxicity against mouse J774 cells by alamar blue assay
Cytotoxicity against mouse J774 cells by alamar blue assay
|
[PMID: 17637068] |
| Jurkat | ED50 |
0.65 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay
Cytotoxic activity against human JurkatE6.1 cell line was measured after 72 h using MTT assay
|
[PMID: 15225732] |
| Jurkat | IC50 |
26.9 nM
Compound: 2
|
Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay
Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay
|
[PMID: 19674909] |
| Jurkat | IC50 |
26.9 μM
Compound: 2
|
Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay
Cytotoxicity against human Jurkat cells after 72 hrs by XTT assay
|
[PMID: 20494586] |
| K562 | IC50 |
112 μM
Compound: 1
|
Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay
Cytotoxicity against paclitaxel-resistant human K562 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| K562 | IC50 |
56 μM
Compound: 1
|
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
Cytotoxicity against human K562 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| K562 | GI50 |
10.8 μg/mL
Compound: 1
|
Cytotoxicity against human K562 cells
Cytotoxicity against human K562 cells
|
[PMID: 18163590] |
| K562 | IC50 |
3.25 μg/mL
Compound: 1
|
Cytotoxicity against human K-562 cells after 72 hrs by MTT assay
Cytotoxicity against human K-562 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| K562 | IC50 |
21.96 μM
Compound: 2
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28671831] |
| KB | ED50 |
>20 μg/mL
Compound: 1
|
In vitro cytotoxicity (antitumor activity) against human epidermoid carcinoma of mouth cell line (KB)
In vitro cytotoxicity (antitumor activity) against human epidermoid carcinoma of mouth cell line (KB)
|
[PMID: 10328313] |
| KB | ED50 |
35.7 μM
Compound: 5
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 15217281] |
| KB | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against drug-resistant human KB cells in absence of vinblastine
Cytotoxicity against drug-resistant human KB cells in absence of vinblastine
|
[PMID: 16562829] |
| KB | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against drug-resistant human KB cells in presence of vinblastine
Cytotoxicity against drug-resistant human KB cells in presence of vinblastine
|
[PMID: 16562829] |
| KB | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 16562829] |
| KB | IC50 |
27.5 μM
Compound: 1
|
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
|
[PMID: 25442310] |
| KB | CC50 |
15.6 μM
Compound: 5
|
Cytotoxic activity in human KB cells by sulforhodamine B assay
Cytotoxic activity in human KB cells by sulforhodamine B assay
|
[PMID: 29120172] |
| KB | IC50 |
28.1 μM
Compound: 5
|
Antiproliferative activity in human KB cells by sulforhodamine B assay
Antiproliferative activity in human KB cells by sulforhodamine B assay
|
[PMID: 29120172] |
| KB | IC50 |
28.7 μM
Compound: 1; BA
|
Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human KB cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| KB | ED50 |
>20 μg/mL
Compound: 1
|
Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.
Cytotoxicity against human epidermoid carcinoma of the mouth (KB) cell line.
|
[PMID: 9873420] |
| KM-20L2 | GI50 |
3.4 μg/mL
Compound: 2
|
Cytotoxicity against human KM20L2 cells
Cytotoxicity against human KM20L2 cells
|
[PMID: 15217278] |
| L02 | IC50 |
35.07 μM
Compound: 2
|
Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human HL-7702 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 28671831] |
| L132 | ED50 |
1.3 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human L132 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| LN-229 | IC50 |
61 μM
Compound: 7
|
Antiproliferative activity against human LN229 cells after 72 hrs by MTS assay
Antiproliferative activity against human LN229 cells after 72 hrs by MTS assay
|
[PMID: 19286375] |
| LN-229 | IC50 |
29 μM
Compound: 1
|
Cytotoxicity against human LN229 cells after 72 hrs by MTS assay
Cytotoxicity against human LN229 cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| LNCaP | ED50 |
27.4 μM
Compound: 5
|
Cytotoxicity against human LNCAP cells
Cytotoxicity against human LNCAP cells
|
[PMID: 15217281] |
| LNCaP | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against human LNCaP cells
Cytotoxicity against human LNCaP cells
|
[PMID: 16562829] |
| Lu1 | ED50 |
40.6 μM
Compound: 5
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 15217281] |
| Lu1 | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against human Lu1 cells
Cytotoxicity against human Lu1 cells
|
[PMID: 16562829] |
| M14 | GI50 |
2.7 μM
Compound: 1
|
Cytotoxicity of compound against human melanoma cell lines (M14-MEL) using MTT assay
Cytotoxicity of compound against human melanoma cell lines (M14-MEL) using MTT assay
|
[PMID: 11527742] |
| M14 | GI50 |
32.6 μg/mL
Compound: 1
|
Cytotoxicity against human M14 cells
Cytotoxicity against human M14 cells
|
[PMID: 18163590] |
| M14 | IC50 |
50 μM
Compound: 4
|
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
|
[PMID: 21954959] |
| MCF7 | GI50 |
1.1 μg/mL
Compound: 2
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 15217278] |
| MCF7 | IC50 |
143 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| MCF7 | GI50 |
>62.5 μg/mL
Compound: 1
|
Cytotoxicity against human MCF7 cells
Cytotoxicity against human MCF7 cells
|
[PMID: 18163590] |
| MCF7 | IC50 |
4 μg/mL
Compound: 9
|
Cytotoxicity against human MCF7 cells by MTT assay
Cytotoxicity against human MCF7 cells by MTT assay
|
[PMID: 18590313] |
| MCF7 | IC50 |
41 μM
Compound: 2
|
Cytotoxicity against human MCF7 cells after 48 hrs
Cytotoxicity against human MCF7 cells after 48 hrs
|
[PMID: 19115839] |
| MCF7 | IC50 |
41 μM
Compound: 3
|
Cytotoxicity against human MCF7 cells by resazurin reduction test
Cytotoxicity against human MCF7 cells by resazurin reduction test
|
[PMID: 19285391] |
| MCF7 | IC50 |
50 μM
Compound: 7
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay
|
[PMID: 19286375] |
| MCF7 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| MCF7 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| MCF7 | IC50 |
12.27 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| MCF7 | IC50 |
12.27 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| MCF7 | IC50 |
30 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| MCF7 | IC50 |
14.9 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| MCF7 | IC50 |
14.8 μM
Compound: 2, BA
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| MCF7 | IC50 |
37 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| MCF7 | IC50 |
14.03 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23973824] |
| MCF7 | IC50 |
14.8 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 24161703] |
| MCF7 | IC50 |
22.61 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| MCF7 | IC50 |
10.527 μM
Compound: BetA
|
Cytotoxicity against human MCF7 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| MCF7 | EC50 |
14.9 μM
Compound: Betulinic acid
|
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| MCF7 | EC50 |
10.2 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| MCF7 | EC50 |
10.2 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| MCF7 | EC50 |
10.2 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 27017553] |
| MCF7 | EC50 |
14.8 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 27142753] |
| MCF7 | EC50 |
10.2 μM
Compound: 4; BA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| MCF7 | EC50 |
10.2 μM
Compound: 5
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| MCF7 | EC50 |
11.4 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| MCF7 | IC50 |
>10 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| MCF7 | GI50 |
11.3 μM
Compound: Betulinic acid
|
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 28754470] |
| MCF7 | CC50 |
49.6 μM
Compound: 5
|
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
Cytotoxic activity in human MCF7 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MCF7 | IC50 |
56.3 μM
Compound: 5
|
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
Antiproliferative activity in human MCF7 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MCF7 | EC50 |
14.8 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 29960206] |
| MCF7 | EC50 |
10.6 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay
|
[PMID: 30056282] |
| MCF7 | IC50 |
>25 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability by trypan blue test
Cytotoxicity against human MCF7 cells assessed as decrease in cell viability by trypan blue test
|
[PMID: 30108714] |
| MCF7 | EC50 |
10.2 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 30278332] |
| MCF7 | EC50 |
12 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925] |
| MCF7 | IC50 |
>40 μM
Compound: 1; BA
|
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| MCF7 | EC50 |
12 μM
Compound: BA
|
Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| MCF7 | IC50 |
0.33 μM
Compound: 1
|
Antitumor activity against human MCF7 cells by SRB assay
Antitumor activity against human MCF7 cells by SRB assay
|
[PMID: 31499360] |
| MCF7 | EC50 |
10.2 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| MCF7 | EC50 |
>30 μM
Compound: 1
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| MCF7 | IC50 |
>30 μM
Compound: BA
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| MCF7 | IC50 |
14.03 μM
Compound: 102
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 96 hrs by SRB assay
|
[PMID: 38308950] |
| MCF7 | IC50 |
16.4 μM
Compound: 102
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs under hypoxic condition by SRB assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs under hypoxic condition by SRB assay
|
[PMID: 38308950] |
| MCF7 | IC50 |
54.8 μM
Compound: 1; BA
|
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| MDA-MB-231 | IC50 |
3.5 μg/mL
Compound: 9
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
[PMID: 18590313] |
| MDA-MB-231 | IC50 |
15.24 μM
Compound: 1
|
Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 3 days by MTT assay
|
[PMID: 19691293] |
| MDA-MB-231 | IC50 |
34.57 μM
Compound: BA
|
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human MDA-MB-231 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| MDA-MB-231 | IC50 |
>20 μM
Compound: BetA
|
Cytotoxicity against human MDA-MB-231 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| MDA-MB-231 | GI50 |
22.9 μM
Compound: Betulinic acid
|
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
Cytotoxicity in human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by SRB assay
|
[PMID: 28754470] |
| MDA-MB-231 | CC50 |
94.3 μM
Compound: 5
|
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
Cytotoxic activity in human MDA-MB-231 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MDA-MB-231 | IC50 |
>500 μM
Compound: 5
|
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
Antiproliferative activity in human MDA-MB-231 cells by sulforhodamine B assay
|
[PMID: 29120172] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: 9
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by CellTiter 96 aqueous one solution assay
|
[PMID: 30057155] |
| MDA-MB-231 | IC50 |
>40 μM
Compound: 1; BA
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition after 72 hrs by sulforhodamine B assay
|
[PMID: 31126820] |
| MDA-MB-231 | IC50 |
19.13 μM
Compound: Betulinic acid
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35217359] |
| MDA-MB-231 | IC50 |
28.85 μM
Compound: BA
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 method
|
[PMID: 38039788] |
| ME-180 | GI50 |
27.8 μg/mL
Compound: 1
|
Cytotoxicity against human ME180 cells
Cytotoxicity against human ME180 cells
|
[PMID: 18163590] |
| MIA PaCa-2 | IC50 |
>20 μg/mL
Compound: 1
|
Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay
Cytotoxicity against human MIA PaCa2 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| MIA PaCa-2 | IC50 |
7 μM
Compound: 1
|
Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26629862] |
| MIA PaCa-2 | IC50 |
>10 μM
Compound: 1
|
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| MIA PaCa-2 | IC50 |
26.7 μM
Compound: Betulinic acid
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35217359] |
| MOLT-4 | ED50 |
1.23 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human MOLT-4 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| MRC5 | IC50 |
32.8 μM
Compound: BA
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28368586] |
| NCI/ADR-RES | IC50 |
38.5 μM
Compound: BA
|
Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human MCF7/ADR cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| NCI-H460 | GI50 |
4.7 μg/mL
Compound: 2
|
Cytotoxicity against human NCI-H460 cells
Cytotoxicity against human NCI-H460 cells
|
[PMID: 15217278] |
| NCI-H460 | GI50 |
29.7 μg/mL
Compound: 1
|
Cytotoxicity against human H460 cells
Cytotoxicity against human H460 cells
|
[PMID: 18163590] |
| Neutrophil | IC50 |
11.12 μg/mL
Compound: 2
|
Immunomodulatory activity in neutrophils assessed as decrease in oxidative burst after 30 min by luminol-enhanced chemiluminescence assay
Immunomodulatory activity in neutrophils assessed as decrease in oxidative burst after 30 min by luminol-enhanced chemiluminescence assay
|
10.1007/s00044-012-0183-y |
| NIH3T3 | GI50 |
>62.5 μg/mL
Compound: 1
|
Cytotoxicity against BALB/c mouse 3T3 cells
Cytotoxicity against BALB/c mouse 3T3 cells
|
[PMID: 18163590] |
| NIH3T3 | IC50 |
4.37 μg/mL
Compound: 1
|
Cytotoxicity against mouse NIH3T3 cells after 72 hrs by MTT assay
Cytotoxicity against mouse NIH3T3 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| NIH3T3 | IC50 |
10 μM
Compound: 2, BA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| NIH3T3 | IC50 |
10 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 24161703] |
| NIH3T3 | IC50 |
>20 μM
Compound: BetA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| NIH3T3 | EC50 |
10 μM
Compound: Betulinic acid
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 26211461] |
| NIH3T3 | EC50 |
16.1 μM
Compound: 1
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 26547057] |
| NIH3T3 | EC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 26750249] |
| NIH3T3 | EC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 27017553] |
| NIH3T3 | EC50 |
16.1 μM
Compound: 4; BA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay
|
[PMID: 27149037] |
| NIH3T3 | EC50 |
16.1 μM
Compound: 5
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 28033541] |
| NIH3T3 | EC50 |
13.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 28169163] |
| NIH3T3 | EC50 |
13.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 29960206] |
| NIH3T3 | EC50 |
12.9 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay
|
[PMID: 30056282] |
| NIH3T3 | EC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 30278332] |
| NIH3T3 | EC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925] |
| NIH3T3 | EC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay
Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| NIH3T3 | EC50 |
16.1 μM
Compound: BA
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability incubated for 96 hrs by SRB assay
|
[PMID: 31718946] |
| NIH3T3 | EC50 |
>30 μM
Compound: 1
|
Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity against mouse NIH3T3 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 32956968] |
| OVCAR-3 | IC50 |
59 μM
Compound: 7
|
Antiproliferative activity against human OVCAR-3 cells after 120 hrs by MTS assay
Antiproliferative activity against human OVCAR-3 cells after 120 hrs by MTS assay
|
[PMID: 19286375] |
| OVCAR-3 | IC50 |
40 μM
Compound: 1
|
Cytotoxicity against human OVCAR-3 cells after 72 hrs by MTS assay
Cytotoxicity against human OVCAR-3 cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| OVCAR-3 | IC50 |
8.366 μM
Compound: BetA
|
Cytotoxicity against human OVCAR3 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against human OVCAR3 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| OVCAR-3 | IC50 |
0.9 μg/mL
Compound: betulinicacidbetulinic acid
|
Cytotoxicity against human OVCAR-3 cells after 48 hrs by MTT assay
Cytotoxicity against human OVCAR-3 cells after 48 hrs by MTT assay
|
[PMID: 9834149] |
| P388 | GI50 |
>10 μg/mL
Compound: 2
|
Cytotoxicity against mouse P388 cells
Cytotoxicity against mouse P388 cells
|
[PMID: 15217278] |
| P815 | IC50 |
41 μM
Compound: 1
|
Cytotoxicity against mouse P815 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse P815 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31499360] |
| PA-1 | ED50 |
>10 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human PA-1 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| PA-1 | IC50 |
11.53 μg/mL
Compound: 1
|
Cytotoxicity against human PA-1 cells after 72 hrs by MTT assay
Cytotoxicity against human PA-1 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| PANC-1 | IC50 |
44 μM
Compound: 2
|
Cytotoxicity against human PANC1 after 24 hrs by fluorometric microculture cytotoxicity assay
Cytotoxicity against human PANC1 after 24 hrs by fluorometric microculture cytotoxicity assay
|
[PMID: 18842418] |
| PANC-1 | IC50 |
32 μM
Compound: 138
|
Inhibition of Gli1-mediated transcription expressed in human PANC1 cells
Inhibition of Gli1-mediated transcription expressed in human PANC1 cells
|
[PMID: 19309080] |
| PANC-1 | IC50 |
10.223 μM
Compound: BetA
|
Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as cell killing effect after 72 hrs by MTT assay
|
[PMID: 26005543] |
| PC-3 | EC50 |
1.9 mM
Compound: 1
|
Cytotoxicity of compound against human prostate adenocarcinoma (PC3) using SRB assay
Cytotoxicity of compound against human prostate adenocarcinoma (PC3) using SRB assay
|
[PMID: 11527742] |
| PC-3 | EC50 |
1.9 μM/mL
Compound: 1
|
Cytotoxicity of compound against human prostate adenocarcinoma (PC3) using SRB assay
Cytotoxicity of compound against human prostate adenocarcinoma (PC3) using SRB assay
|
[PMID: 11527742] |
| PC-3 | IC50 |
91 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| PC-3 | GI50 |
31.3 μg/mL
Compound: 1
|
Cytotoxicity against human PC3 cells
Cytotoxicity against human PC3 cells
|
[PMID: 18163590] |
| PC-3 | IC50 |
40 μM
Compound: 2
|
Cytotoxicity against human PC3 cells after 48 hrs
Cytotoxicity against human PC3 cells after 48 hrs
|
[PMID: 19115839] |
| PC-3 | IC50 |
40 μM
Compound: 3
|
Cytotoxicity against human PC3 cells by resazurin reduction test
Cytotoxicity against human PC3 cells by resazurin reduction test
|
[PMID: 19285391] |
| PC-3 | IC50 |
21.5 μM
Compound: 2
|
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
Cytotoxicity against human PC3 cells after 72 hrs by MTT assay
|
[PMID: 20494586] |
| PC-3 | IC50 |
37 μM
Compound: 1
|
Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| PC-3 | IC50 |
27.51 μM
Compound: BA
|
Cytotoxicity against human PC3 cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| PC-3 | IC50 |
7 μM
Compound: 1
|
Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as cell growth inhibition after 48 hrs by MTT assay
|
[PMID: 26629862] |
| PC-3 | IC50 |
>10 μM
Compound: 1
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 48 hrs by SRB assay
|
[PMID: 28500966] |
| PC-3 | IC50 |
>100 μM
Compound: 1; BA
|
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| Raji | IC50 |
403 molar ratio
Compound: 1
|
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA
Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as EA induction after 48 hrs relative to TPA
|
[PMID: 19481937] |
| RAW264.7 | IC50 |
42.5 μM
Compound: 110
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production
|
[PMID: 31255927] |
| RAW264.7 | CC50 |
50.64 μM
Compound: BA
|
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured for 96 hrs by MTT assay
Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability measured for 96 hrs by MTT assay
|
[PMID: 34491054] |
| RAW264.7 | IC50 |
32.38 μM
Compound: BA
|
Inhibition of RANKL/M-CSF-induced osteoclastogenesis in mouse RAW264.7 cells measured for 4 days by TRAP staining based assay
Inhibition of RANKL/M-CSF-induced osteoclastogenesis in mouse RAW264.7 cells measured for 4 days by TRAP staining based assay
|
[PMID: 34491054] |
| RAW264.7 | IC50 |
>100 μM
Compound: 4
|
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production pretreated with compounds for 15 mins followed by HMGB1 stimulation measured after 24 hrs by Griess reagent based assay
Antiinflammatory activity against mouse RAW264.7 cells assessed as inhibition of HMGB1-induced NO production pretreated with compounds for 15 mins followed by HMGB1 stimulation measured after 24 hrs by Griess reagent based assay
|
[PMID: 34800877] |
| RD | IC50 |
23.95 μM
Compound: Betulinic acid
|
Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay
Cytotoxicity against human TE-32 cells after 72 hrs ny MTT assay
|
[PMID: 23974020] |
| SF-268 | GI50 |
0.86 μg/mL
Compound: 2
|
Cytotoxicity against human SF268 cells
Cytotoxicity against human SF268 cells
|
[PMID: 15217278] |
| SF-295 | IC50 |
22 μM
Compound: 1
|
Cytotoxicity against human SF295 cells after 48 hrs by SRB assay
Cytotoxicity against human SF295 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| SH-SY5Y | EC50 |
4.3 μM
Compound: Betulinic acid
|
Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 1-methyl-4-phenylpyridinium ion-induced cell death after 48 hrs by MTT assay
Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 1-methyl-4-phenylpyridinium ion-induced cell death after 48 hrs by MTT assay
|
[PMID: 27420919] |
| SiHa | CC50 |
28.9 μM
Compound: 5
|
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
Cytotoxic activity in human SiHa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| SiHa | IC50 |
70.1 μM
Compound: 5
|
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
Antiproliferative activity in human SiHa cells by sulforhodamine B assay
|
[PMID: 29120172] |
| SK-MEL | IC50 |
35 μM
Compound: 2
|
Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL
Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL
|
[PMID: 10450948] |
| SK-MEL-2 | ED50 |
4.2 μg/mL
Compound: 1
|
In vitro cytotoxicity (antitumor activity) against human melanoma (MEL-2) cell lines
In vitro cytotoxicity (antitumor activity) against human melanoma (MEL-2) cell lines
|
[PMID: 10328313] |
| SK-MEL-2 | GI50 |
3.2 μM
Compound: 1
|
Cytotoxicity of compound against human melanoma cell lines (SK-MEL-2) using MTT assay
Cytotoxicity of compound against human melanoma cell lines (SK-MEL-2) using MTT assay
|
[PMID: 11527742] |
| SK-MEL-2 | EC50 |
2.2 mM
Compound: 1
|
Cytotoxicity of compound against SK-MEL-2 using SRB assay
Cytotoxicity of compound against SK-MEL-2 using SRB assay
|
[PMID: 11527742] |
| SK-MEL-2 | EC50 |
2.2 μM/mL
Compound: 1
|
Cytotoxicity of compound against SK-MEL-2 using SRB assay
Cytotoxicity of compound against SK-MEL-2 using SRB assay
|
[PMID: 11527742] |
| SK-MEL-2 | ED50 |
7.62 μg/mL
Compound: BA (Betulinic acid)
|
Cytotoxic activity towards M2 cells (SK-MEL-2)
Cytotoxic activity towards M2 cells (SK-MEL-2)
|
[PMID: 12951080] |
| SK-MEL-2 | ED50 |
1.3 μM
Compound: 5
|
Cytotoxicity against human SK-MEL-2 cells
Cytotoxicity against human SK-MEL-2 cells
|
[PMID: 15217281] |
| SK-MEL-2 | IC50 |
21 μM
Compound: 1
|
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTT assay
|
[PMID: 15270560] |
| SK-MEL-2 | IC50 |
33 μM
Compound: 7
|
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTS assay
Antiproliferative activity against human SK-MEL-2 cells after 72 hrs by MTS assay
|
[PMID: 19286375] |
| SK-MEL-2 | IC50 |
17.44 μM
Compound: 7
|
Cytotoxicity against human SK-MEL-2 cells by SRB assay
Cytotoxicity against human SK-MEL-2 cells by SRB assay
|
[PMID: 20176479] |
| SK-MEL-2 | IC50 |
7 μM
Compound: 1
|
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTS assay
Cytotoxicity against human SK-MEL-2 cells after 72 hrs by MTS assay
|
[PMID: 20719505] |
| SK-MEL-2 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human SK-MEL-2 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 28358502] |
| SK-MEL-2 | ED50 |
1.2 μg/mL
Compound: 1
|
Cytotoxicity against cultured human melanoma (MEL-2) cell line.
Cytotoxicity against cultured human melanoma (MEL-2) cell line.
|
[PMID: 9873420] |
| SK-N-SH | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against human SKNSH cells
Cytotoxicity against human SKNSH cells
|
[PMID: 16562829] |
| SK-OV-3 | IC50 |
17.68 μM
Compound: 7
|
Cytotoxicity against human SKOV3 cells by SRB assay
Cytotoxicity against human SKOV3 cells by SRB assay
|
[PMID: 20176479] |
| SK-OV-3 | IC50 |
>10 μM
Compound: 17
|
Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth by SRB assay
Cytotoxicity against human SKOV3 cells assessed as inhibition of cell growth by SRB assay
|
[PMID: 28358502] |
| SMMC-7721 | IC50 |
43.6 μM
Compound: 1; BA
|
Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| SW-1736 | IC50 |
11.6 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| SW-1736 | IC50 |
11.6 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| SW-1736 | IC50 |
13.09 μM
Compound: 1
|
Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| SW-1736 | IC50 |
13.09 μM
Compound: 1
|
Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay
Cytotoxicity against human SW1736 cells after 96 hrs by SRB colorimetric assay
|
[PMID: 20472329] |
| SW-1736 | IC50 |
11.6 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| SW-1736 | IC50 |
11.6 μM
Compound: 2, BA
|
Cytotoxicity against human SW1736 cells assessed as cell viability after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as cell viability after 96 hrs by SRB assay
|
[PMID: 23245801] |
| SW-1736 | EC50 |
16.4 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910] |
| SW-1736 | EC50 |
18.3 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells after 96 hrs by SRB assay
|
[PMID: 29960206] |
| SW-1736 | EC50 |
14.8 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine-B assay
Cytotoxicity against human SW1736 cells after 96 hrs by sulforhodamine-B assay
|
[PMID: 30056282] |
| SW-1736 | EC50 |
16.4 μM
Compound: BA
|
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925] |
| SW-1736 | EC50 |
16.4 μM
Compound: BA
|
Anticancer activity against human SW1736 cells measured after 96 hrs by sulforhodamine B assay
Anticancer activity against human SW1736 cells measured after 96 hrs by sulforhodamine B assay
|
[PMID: 31330447] |
| SW480 | IC50 |
6.4 μM
Compound: BA
|
Cytotoxicity against human SW480 cells after 96 hrs by SRB assay
Cytotoxicity against human SW480 cells after 96 hrs by SRB assay
|
[PMID: 20034802] |
| SW480 | IC50 |
6.4 μM
Compound: BA
|
Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20299226] |
| SW480 | IC50 |
6.48 μM
Compound: 1
|
Cytotoxicity against human SW480 cells after 96 hrs by SRB assay
Cytotoxicity against human SW480 cells after 96 hrs by SRB assay
|
[PMID: 20451375] |
| SW480 | IC50 |
6.4 μM
Compound: BA
|
Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay
Cytotoxicity against human SW480 cells after 96 hrs by sulforhodamine B assay
|
[PMID: 20846866] |
| SW-620 | IC50 |
13.26 μg/mL
Compound: 1
|
Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
Cytotoxicity against human SW620 cells after 72 hrs by MTT assay
|
[PMID: 18752941] |
| SW-620 | IC50 |
54.34 μM
Compound: 1; BA
|
Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
Antiproliferative activity against human SW620 cells assessed as inhibition of cell growth incubated for 48 hrs by CCK-8 reagent based spectrophotometric analysis
|
[PMID: 38964258] |
| SW626 | ED50 |
>20 μg/mL
Compound: betulinic acid
|
Cytotoxicity against human SW626 cells
Cytotoxicity against human SW626 cells
|
[PMID: 16562829] |
| SW948 | IC50 |
10.5 μM
Compound: 1
|
Antiproliferative activity against human SW948 cells after 3 days by XTT assay
Antiproliferative activity against human SW948 cells after 3 days by XTT assay
|
[PMID: 19691293] |
| T47D | IC50 |
15.56 μM
Compound: BA
|
Cytotoxicity against human T47D cells assessed as growth inhibition after 96 hrs by SRB assay
Cytotoxicity against human T47D cells assessed as growth inhibition after 96 hrs by SRB assay
|
[PMID: 25817774] |
| THP-1 | IC50 |
20 μM
Compound: 1
|
Cytotoxicity against human THP1 cells after 48 hrs by SRB assay
Cytotoxicity against human THP1 cells after 48 hrs by SRB assay
|
[PMID: 23584541] |
| U-937 | ED50 |
0.69 μg/mL
Compound: Betulinic acid
|
Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay
Cytotoxic activity against human U937 cell line was measured after 72 hr using MTT assay
|
[PMID: 15225732] |
| UACC-257 | GI50 |
1.5 μM
Compound: 1
|
Cytotoxicity of compound against human melanoma cell lines (UACC-257) using MTT assay
Cytotoxicity of compound against human melanoma cell lines (UACC-257) using MTT assay
|
[PMID: 11527742] |
| Vero | CC50 |
150 μM
Compound: 13
|
Cytotoxicity against Vero E6 cells by MTT assay
Cytotoxicity against Vero E6 cells by MTT assay
|
[PMID: 17663539] |
| Vero | EC50 |
>10 μM
Compound: 13
|
Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
|
[PMID: 17663539] |
| Vero | GI50 |
30.6 μg/mL
Compound: 1
|
Cytotoxicity against african green monkey Vero cells
Cytotoxicity against african green monkey Vero cells
|
[PMID: 18163590] |
| Vero | CC50 |
>100 μM
Compound: 1, Betulinic acid
|
Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by Alamar Blue assay
Cytotoxicity against African green monkey Vero cells assessed as cell viability after 48 hrs by Alamar Blue assay
|
[PMID: 26112446] |
| Vero | IC50 |
1.6 μM
Compound: 1, Betulinic acid
|
Antiviral activity against HSV-2 186 infected in African green monkey Vero cells assessed as inhibition of viral yield after 48 hrs by crystal violet staining
Antiviral activity against HSV-2 186 infected in African green monkey Vero cells assessed as inhibition of viral yield after 48 hrs by crystal violet staining
|
[PMID: 26112446] |
| Vero | CC50 |
38.1 μM
Compound: 5
|
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
Cytotoxic activity in African green monkey Vero cells by sulforhodamine B assay
|
[PMID: 29120172] |
| Vero | IC50 |
72.1 μM
Compound: 5
|
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
Antiproliferative activity in African green monkey Vero cells by sulforhodamine B assay
|
[PMID: 29120172] |
| Vero | CC50 |
>400 μM
Compound: BA
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTT assay
|
[PMID: 29326018] |
| WI-38 | IC50 |
1.3 μM
Compound: 12
|
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
Cytotoxicity against human WI 38 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
| WI-38 VA13 | IC50 |
11.6 μM
Compound: 12
|
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
Cytotoxicity against human VA13 cells after 48 hrs by WST-8 assay
|
[PMID: 15730243] |
Betulinic acid is a eukaryotic topoisomerase I inhibitor, with an IC50 of 5 μM, and prevents topoisomerase I-DNA interaction[1]. Betulinic acid (10, 20, 40, 80, and 160 μM) significantly suppresses MDA-MB-231 cell viability in a time- and dose-dependent manner after treatment for 24 or 48 h. Betulinic acid (20, 40 μM) causes decrease in Bcl-2 expression of MDA-MB-231 cells. Betulinic acid also induces morphological changes of MDA-MB-231 cells at 20 μM, and leads to ultrastructure changes of MDA-MB-231 cells at 40 μM[2]. Betulinic acid shows anti-HIV activities, with an EC50 of 1.4 μM in acutely infected H9 lymphocytes[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 472-15-1
-
Appearance Solid
-
Molecular Weight 456.70
-
Formula C30H48O3
-
Color White to off-white
-
SMILES
[H][C@@]12CC[C@@]3(C)[C@]4(C)CC[C@]5(C(O)=O)[C@@]([C@H](C(C)=C)CC5)([H])[C@@](CC[C@@]([H])3[C@@]1(C)CC[C@H](O)C2(C)C)4[H]
-
Synonyms
Lupatic acid; Betulic acid
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (35)
-
Journal Impact Factor
-
Most Recent
-
Sci Bull
Engineering redirected NF-κB/OIP5 expression programs to enhance tumor responses to chemotherapy in bladder cancer. [Abstract]2023 Dec 30;68(24):3207-3224. PMID: 37993335 -
Theranostics
Requirement of hippocampal DG nNOS-CAPON dissociation for the anxiolytic and antidepressant effects of fluoxetine. [Abstract]2022 May 1;12(8):3656-3675. PMID: 35664081
Betulinic acid purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 May 1;12(8):3656-3675. [Abstract]
Betulinic acid (20 μM) significantly reversed the down-regulation of nNOS and CAPON expression induced by fluoxetine.
-
Pharmacol Res
2024 May 9:204:107208. PMID: 38729587 -
Int J Biol Sci
Betulinic acid inhibits pyroptosis in spinal cord injury by augmenting autophagy via the AMPK-mTOR-TFEB signaling pathway. [Abstract]2021 Mar 11;17(4):1138-1152. PMID: 33867836
Betulinic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Mar 11;17(4):1138-1152. [Abstract]
Longitudinal spinal cord sections from the indicated groups at day 14 were analyzed by HE staining and Masson staining.
Betulinic acid purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2021 Mar 11;17(4):1138-1152. [Abstract]
With Betulinic acid (BA) (20 mg/kg, i.p.) treatment, animals had higher neuronal MAP2 expression, and more SYN-positive synapses onto ventral motor neurons compared with the untreated SCI group.
-
-
Phytomedicine
Bruceantin inhibits the c-Myc/RL27A axis to suppress tumor progression in hepatocellular carcinoma. [Abstract]2025 Dec 24:150:157740. PMID: 41477978 -
J Transl Med
Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial-mesenchymal transition in chronic hepatic injury. [Abstract]2025 Nov 13;23(1):1282. PMID: 41233877
Betulinic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Nov 13;23(1):1282. [Abstract]
Serum levels of ALT and AST were measured to assess liver function in Betulinic acid (BA) (20, 50 mg/kg, i.g.) treatment group significantly reduced, providing a biochemical evaluation of hepatic injury.
Betulinic acid purchased from MedChemExpress. Usage Cited in: J Transl Med. 2025 Nov 13;23(1):1282. [Abstract]
Representative images illustrating the morphological alterations in the liver of mice from different treatment groups, highlighting the effects of Betulinic acid (BA) (20, 50 mg/kg, i.g.) on hepatic appearance.
-
-
Biochem Pharmacol
Mairin polarizes Macrophages into M2-phenotype and alleviates Ulcerative colitis through activating IRF4-CD5L pathway. [Abstract]2026 May:247:117771. PMID: 41651133 -
-
Nutrients
Betulinic Acid Reduces Intestinal Inflammation and Enhances Intestinal Tight Junctions by Modulating the PPAR-γ/NF-κB Signaling Pathway in Intestinal Cells and Organoids. [Abstract]2025 Jun 20;17(13):2052. PMID: 40647158 -
Microb Cell Fact
Boosting the biosynthesis of betulinic acid and related triterpenoids in Yarrowia lipolytica via multimodular metabolic engineering. [Abstract]2019 May 3;18(1):77. PMID: 31053076 -
Front Pharmacol
Betulinic Acid Enhances the Viability of Random-Pattern Skin Flaps by Activating Autophagy. [Abstract]2019 Sep 13;10:1017. PMID: 31572190
Betulinic acid purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2019 Sep 13;10:1017. [Abstract]
Immunofluorescence is performed to determine the LC3II expression level to show the autophagosomes in the cells of the skin flaps: autophagosomes (green) in the dermis in area II; nuclei counterstained with DAPI (blue).
-
Int Immunopharmacol
ACE2/Ang(1-7)/MasR axis exerts protective effects on lung ischemia/reperfusion injury via NF-κB-dependent mitochondrial adaptation and epithelial cell pyroptosis. [Abstract]2025 Aug 11:164:115325. PMID: 40795499 -
mBio
Gut microbe-derived betulinic acid alleviates sepsis-induced acute liver injury by inhibiting macrophage NLRP3 inflammasome in mice. [Abstract]2025 Jan 31:e0302024. PMID: 39887250 -
Front Cell Dev Biol
Retinoic Acid Inhibits Tumor-Associated Mesenchymal Stromal Cell Transformation in Melanoma. [Abstract]2021 Apr 6:9:658757. PMID: 33889575 -
J Cell Mol Med
Betulinic Acid Suppresses UBE2T Expression via MAPK/ERK Inhibition to Block FANCI and FANCD2 Monoubiquitination in Glioblastoma. [Abstract]2026 Jan;30(1):e71000. PMID: 41486508 -
Drug Dev Res
Betulinic Acid Alleviates Acute Pancreatitis by Promoting SIRT1-PINK1-Mediated Mitophagy in Acinar Cells. [Abstract]2025 Aug;86(5):e70140. PMID: 40787703 -
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Aging (Albany NY)
Betulinic acid induces autophagy-dependent apoptosis via Bmi-1/ROS/AMPK-mTOR-ULK1 axis in human bladder cancer cells. [Abstract]2021 Sep 12;13(17):21251-21267. PMID: 34510030 -
Heliyon
Betulinic acid arrests cell cycle at G2/M phase by up-regulating metallothionein 1G inhibiting proliferation of colon cancer cells. [Abstract]2023 Dec 29;10(1):e23833. PMID: 38261922 -
Heliyon
Inhibition of Pard3 promotes breast cancer metastasis via the USP28 mediated deubiquitination of Snail1. [Abstract]2023 Nov 20;9(12):e22599. PMID: 38076191 -
Heliyon
HTRA1 from OVX rat osteoclasts causes detrimental effects on endplate chondrocytes through NF-κB. [Abstract]2023 Jun 22;9(6):e17595. PMID: 37416639 -
Mol Med Rep
PDCD4 promotes inflammation/fibrosis by activating the PPAR‑γ/NF‑κB pathway in mouse atrial myocytes. [Abstract]2024 Nov;30(5):209. PMID: 39301631 -
Mol Med Rep
Fxyd5 activates the NF‑κB pathway and is involved in chondrocytes inflammation and extracellular matrix degradation. [Abstract]2022 Apr;25(4):134. PMID: 35191523 -
Wound Repair Regen
Foamy macrophages potentially inhibit tuberculous wound healing by inhibiting the TLRs/NF-κB signalling pathway. [Abstract]2022 May;30(3):376-396. PMID: 35384137 -
Gut Liver
GATA4 Forms a Positive Feedback Loop with CDX2 to Transactivate MUC2 in Bile Acids-Induced Gastric Intestinal Metaplasia. [Abstract]2024 May 15;18(3):414-425. PMID: 36860162 -
Cell Immunol
2022 Feb:372:104475. PMID: 35063904 -
J Cell Biochem
Rabdosichuanin C inhibits productions of pro-inflammatory mediators regulated by NF-κB signaling in LPS-stimulated RAW264.7 cells. [Abstract]2023 Nov;124(11):1667-1684. PMID: 37850620 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Virus Res
Porcine reproductive and respiratory syndrome virus regulates lipid droplet accumulation in lipid metabolic pathways to promote viral replication. [Abstract]2023 Aug:333:199139. PMID: 37217033 -
J Gene Med
Betulinic Acid Inhibits Glioma Progression by Inducing Ferroptosis Through the PI3K/Akt and NRF2/HO-1 Pathways. [Abstract]2025 Feb;27(2):e70011. PMID: 39965807 -
Med Sci Monit
Peroxiredoxin2 (Prdx2) Reduces Oxidative Stress and Apoptosis of Myocardial Cells Induced by Acute Myocardial Infarction by Inhibiting the TLR4/Nuclear Factor kappa B (NF-κB) Signaling Pathway. [Abstract]2020 Dec 3:26:e926281. PMID: 33268762 -
Solvent & Solubility
DMSO : 11.67 mg/mL (25.55 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
CCK-8 is used in the assay. MDA-MB-231 cells are cultured in 96-well plates at a density of 2 × 103 cells/well and then treated with DMSO vehicle or various concentrations of Betulinic acid ranging from 5 µM to 160 µM in 100 µL of medium for the indicated times. After the treatment period, the medium in each well is replaced with 110 µL of medium containing 10 µL of the CCK-8 mixture, and the plates are incubated for 1 h and 30 min at 37°C. The absorbance at a wavelength of 450 nm is measured with a microplate reader[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Female Swiss albino mice are administered vehicle (5% v/v DMSO in peanut oil) or Betulinic acid (3, 10 or 30 mg/kg) in vehicle, orally. After 1 h, acetic acid (300 mg/kg) is administered by intraperitoneal route and number of writhing response of each animal is counted for 20 min by an observer who is blind to the treatments. Writhing response is when animal rubs its abdomen on surface of table/floor with elongation of the body and extension of the hind limbs[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Chowdhury AR, et al. Betulinic acid, a potent inhibitor of eukaryotic topoisomerase I: identification of the inhibitory step, the major functional group responsible and development of more potent derivatives. Med Sci Monit. 2002 Jul;8(7):BR254-65. [Content Brief]
[2]. Gao Y, et al. Betulinic acid induces apoptosis and ultrastructural changes in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. 2018 Jan-Feb;42(1):49-54. [Content Brief]
[3]. Kalra J, et al. Betulinic acid alleviates dextran sulfate sodium-induced colitis and visceral pain in mice. Naunyn Schmiedebergs Arch Pharmacol. 2017 Dec 26. [Content Brief]
[4]. Hashimoto F, et al. Anti-AIDS agents--XXVII. Synthesis and anti-HIV activity of betulinic acid and dihydrobetulinic acid derivatives. Bioorg Med Chem. 1997 Dec;5(12):2133-43. [Content Brief]
[5]. Kasperczyk H, et al. Betulinic acid as new activator of NF-kappaB: molecular mechanisms and implications for cancer therapy. Oncogene. 2005 Oct 20;24(46):6945-56. [Content Brief]
[6]. Fernandes S, et al. Betulinic Acid for Glioblastoma Treatment: Reality, Challenges and Perspectives. Int J Mol Sci. 2024 Feb 9;25(4):2108. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1896 mL | 10.9481 mL | 21.8962 mL | 54.7405 mL |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3792 mL | 10.9481 mL | |
| 10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL | 5.4741 mL | |
| 15 mM | 0.1460 mL | 0.7299 mL | 1.4597 mL | 3.6494 mL | |
| 20 mM | 0.1095 mL | 0.5474 mL | 1.0948 mL | 2.7370 mL | |
| 25 mM | 0.0876 mL | 0.4379 mL | 0.8758 mL | 2.1896 mL |